Improvement of defective insulin responses to glucose, arginine, and beta-adrenergic stimulation in diabetics by sodium salicylate.
D001120:Arginine / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors; D003920:Diabetes Mellitus / Q000378:metabolism*; D005947:Glucose / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007545:Isoproterenol / Q000494:pharmacology; D011458:Prostaglandins E / Q000494:pharmacology*; D012459:Salicylates / Q000494:pharmacology*; D012636:Secretory Rate / Q000187:drug effects
D016861:Cyclooxygenase Inhibitors; D007328:Insulin; D011458:Prostaglandins E; D012459:Salicylates; D001120:Arginine; D005947:Glucose; D007545:Isoproterenol